<PAGE> 1
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
<TABLE>
<S> <C>
[ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission
[X] Definitive Proxy Statement Only (as permitted by Rule 14a-6(e)(2))
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
</TABLE>
COMPREHENSIVE CARE CORPORATION
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
----------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
----------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
----------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
----------------------------------------------------------------------
(5) Total fee paid:
----------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount previously paid:
----------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
----------------------------------------------------------------------
(3) Filing Party:
----------------------------------------------------------------------
(4) Date Filed:
----------------------------------------------------------------------
<PAGE> 2
[COMPREHENSIVE CARE CORPORATION LOGO]
September 30, 1998
Dear Comprehensive Care Corporation Stockholder:
On behalf of the Board of Directors and management of your Company, I
cordially invite you to attend our Annual Meeting of Stockholders of
Comprehensive Care Corporation (the "Company") on Tuesday, November 17, 1998 at
10:00 a.m. Eastern Standard Time, at the principal offices of the Company,
located at 4200 West Cypress Street, Suite 300, Tampa, Florida 33607, and any
adjournments or postponements thereof.
I urge you to attend the Annual Meeting to give us an opportunity to meet
you personally and to answer any questions you may have.
I hope that you will be able to attend the Annual Meeting in person.
Whether or not you plan to attend the Annual Meeting, please sign and promptly
return the enclosed proxy card in the return postage paid envelope provided.
I look forward to seeing you at the Annual Meeting of Stockholders.
Sincerely,
/s/ Chriss W. Street
Chriss W. Street
Chairman of the Board, President
and Chief Executive Officer
<PAGE> 3
COMPREHENSIVE CARE CORPORATION
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD TUESDAY, NOVEMBER 17, 1998
----------------------------------
To the Stockholders of Comprehensive Care Corporation:
Notice is hereby given that the 1998 Annual Meeting of Stockholders of
Comprehensive Care Corporation (the "Company") will be held at the principal
offices of the Company, located at 4200 West Cypress Street, Suite 300, Tampa,
Florida 33607 on Tuesday, November 17, 1998 at 10:00 a.m. Eastern Standard Time,
and any adjournments or postponements thereof for the following purposes:
1. To elect one Class III director to serve until the year 2001
Annual Meeting of Stockholders and until his successor is elected
and qualified;
2. To act upon a proposal to amend the Comprehensive Care
Corporation 1995 Incentive Plan as amended to increase the number
of shares authorized and available for issuance pursuant to
grants made thereunder from 600,000 to 1,000,000 shares; and
3. To consider and transact such other business as may properly come
before the meeting or any adjournment thereof.
Stockholders of record at the close of business on September 29, 1998,
are entitled to vote at the meeting. A list of stockholders entitled to vote at
the meeting will be available for inspection at the principal offices of the
Company.
By Order of the Board of Directors,
/s/ Courtney Watson
Courtney Watson
Secretary
September 30, 1998
YOU ARE CORDIALLY INVITED TO ATTEND THE MEETING IN PERSON. WHETHER OR NOT
YOU PLAN TO ATTEND THE MEETING, PLEASE SIGN THE ACCOMPANYING PROXY AND MAIL IT
IN THE ENCLOSED POSTAGE PREPAID ENVELOPE. YOUR PROMPT RESPONSE WILL SAVE THE
EXPENSE OF A FOLLOW-UP MAILING.
<PAGE> 4
COMPREHENSIVE CARE CORPORATION
4200 WEST CYPRESS STREET, SUITE 300
TAMPA, FLORIDA 33607
(813) 876-5036
------------------
PROXY STATEMENT
FOR
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 17, 1998
-------------------
The Board of Directors of Comprehensive Care Corporation (the "Company")
solicits your proxy for use at the 1998 Annual Meeting of Stockholders (the
"Annual Meeting") to be held on Tuesday, November 17, 1998 at 10:00 a.m.,
Eastern Standard Time, at the principal offices of the Company located at 4200
West Cypress Street, Suite 300, Tampa, Florida 33607, and any adjournments or
postponements thereof. This Proxy Statement and the accompanying form of proxy
are first being mailed on or about September 30, 1998. Following this mailing,
certain officers and employees of the Company may solicit proxies by mail,
telephone, telecopy or in person, without additional compensation. In addition,
the Company has engaged Continental Stock Transfer & Trust Company to assist in
this proxy solicitation for a fee of $5,000 plus expenses. Upon request, the
Company will reimburse brokers and other persons holding shares for others for
their expenses in forwarding copies of the proxy soliciting material to the
beneficial owners of such shares. All costs of solicitation will be paid by the
Company.
The shares held by each person giving a proxy in the accompanying form
will be voted at the meeting in accordance with any instructions specified in
the proxy. If no instructions are specified, the shares will be voted; FOR the
election as a Class III director of the nominee specified herein and FOR the
proposal to amend the 1995 Incentive Plan. A proxy may be revoked by the person
giving it any time before its exercise by sending a written notice of such
revocation or a later-dated proxy to the Secretary of the Company at the above
address or by attending the Annual Meeting and voting in person. Attendance at
the Annual Meeting will not by itself revoke a proxy.
Only stockholders of record at the close of business on September 29,
1998 are entitled to notice of, and to vote at, the Annual Meeting. As of that
date, 3,474,333 shares of common stock, $.01 par value per share ("Common
Stock"), were outstanding and held of record by stockholders. Stockholders are
entitled to one vote for each share of Common Stock held.
The presence in person or by proxy of the holders of a majority of the
outstanding shares of Common Stock will constitute a quorum for the transaction
of business at the Annual Meeting. Directors are elected by a plurality of the
votes present in person or by proxy and entitled to vote. Except as set forth in
the next paragraph, approval of any other matter that may properly come before
the Annual Meeting requires the affirmative vote of a majority of the shares
present in person or by proxy and entitled to vote. Abstentions will therefore
have the effect of negative votes with respect to any matter presented at the
Annual Meeting, while broker non-votes will have no effect on any matter
presented. If authority to vote for the nominee is withheld on a proxy card, no
vote will be cast with respect to the shares represented thereby and the outcome
of the election will not be affected.
The New York Stock Exchange ("NYSE") Shareholder Approval Policy
requires, in many instances, the approval of the listed company's shareholders
option plans, in which the directors or officers participate for the shares to
be listed on the NYSE. In order for the approval to be effectively given on
Proposal 2, at least a majority of the outstanding Common Stock must cast votes
in person or by proxy (counting the total votes
<PAGE> 5
cast for, against, abstaining, or indicating no instruction); and a majority of
the outstanding Common Stock voting must approve Proposal 2.
PRINCIPAL STOCKHOLDERS
The following table sets forth information concerning the beneficial
ownership of Common Stock by each person know by the Company to be a beneficial
owner of more than 5% of the outstanding shares of Common Stock, the directors
of the Company, the executive officers named in the Summary Compensation Table
included elsewhere herein and all directors and executive officers as a group.
Such information is given as of September 29, 1998, the record date. According
to rules adopted by the Securities and Exchange Commission, a person is the
"beneficial owner" of securities if he or she has, or shares, the power to vote
such securities or to direct their investment. Except as otherwise noted, the
indicated owners have sole voting and investment power with respect to shares
beneficially owned. An asterisk in the percent of Class column indicates
beneficial ownership of less than 1% of the outstanding Common Stock.
NAME OF AMOUNT AND NATURE OF PERCENT
BENEFICIAL OWNER BENEFICIAL OWNERSHIP OF CLASS
- ----------------------- -------------------- --------
Lindner Growth Fund(1) 649,620 18.7%
Chriss W. Street(2) 306,760 8.2%
Mary Jane Johnson(3) 21,500 *
J. Marvin Feigenbaum(4) 19,416 *
William H. Boucher(5) 12,600 *
Joni Cummings(6) 3,000 *
A. Richard Pantuliano(7) 2,500 *
H.G. Whittington(8)(9) 1,000 *
Robert J. Landis(10) 500 *
All executive officers and 367,276(11) 9.7%
directors as a group (9 persons)
- -------------------
(1) The mailing address of Lindner Growth Fund is c/o Ryback Management
Corporation, 7711 Carondelet Avenue, Suite 700, St. Louis, Missouri 63105.
Includes approximately 343,820 shares as the result of the conversion of
41,260 shares of Preferred Stock and 250,000 shares sold under an Amended
common Stock Purchase Agreement dated June 29, 1995. The shares and
convertible debt, as described in its Amendment Number 4 of Schedule 13G
dated January 23, 1998, are held in the Lindner Growth Fund.
(2) Includes 12,260 shares held directly and 245,000 shares subject to options
that are presently exercisable or exercisable within 60 days. Also includes
49,500 vested shares under a Restricted Stock Grant. Does not include
100,000 shares subject to options which are not presently exercisable, and
which are subject to various vesting conditions. Mr. Street's mailing
address is c/o Comprehensive Care Corporation, 1111 Bayside Drive, Suite
100, Corona del Mar, California 92625.
2
<PAGE> 6
(3) Includes 21,500 shares subject to options that are presently exercisable or
exercisable within 60 days of the record date. Does not include 18,500
shares subject to options which are not presently exercisable, and which
are subject to time vesting conditions.
(4) Includes 250 shares held directly and 19,166 shares subject to options that
are presently exercisable or exercisable within 60 days of the record date.
Does not include 16,666 shares subject to options which are not presently
exercisable, and which are subject to time vesting conditions.
(5) Includes 100 shares held directly and 12,500 shares subject to options that
are presently exercisable or exercisable within 60 days of the record date.
Does not include 10,000 shares subject to options which are not presently
exercisable.
(6) Includes 3,000 shares subject to options that are presently exercisable or
exercisable within 60 days of the record date. Does not include 17,000
shares subject to options which are not presently exercisable, and which
are subject to time vesting conditions.
(7) Includes 2,500 shares subject to options that are presently exercisable or
exercisable within 60 days of the record date. Does not include 15,000
shares subject to options which are not presently exercisable, and which
are subject to time vesting conditions.
(8) Includes 1,000 shares subject to options that are presently exercisable or
exercisable within 60 days. Does not include 19,000 shares subject to
options which are not presently exercisable, and which are subject to time
vesting conditions.
(9) On August 15, 1998, Dr. Whittington resigned from the Company as an officer
and from all positions. Inclusion of Dr. Whittington on this table is only
by reason of inclusion in the Summary Compensation Table.
(10) Mr. Landis was appointed Executive Vice President, Chief Financial Officer
and Treasurer of the Company on July 2, 1998. Includes 500 shares held
directly. Does not include 87,500 shares subject to options which are not
presently exercisable.
(11) Includes a total of 13,110 shares held directly and 304,666 shares subject
to outstanding options that are presently exercisable or exercisable within
60 days of the record date and 49,500 shares of restricted stock over which
the holder has sole voting power.
3
<PAGE> 7
PROPOSAL 1 - ELECTION OF ONE CLASS III DIRECTOR
The number of members that comprise the entire Board of Directors is
four in number, of which two are Class I directors; one is a Class II director;
and one is a Class III director. The three classes serve staggered three-year
terms. Directors for each class are elected at the Annual Meeting of
Stockholders held in the year in which the term for such class expires and serve
for three years. Messrs. William H. Boucher and J. Marvin Feigenbaum are Class I
directors whose terms expire at the 2000 Annual Meeting. Mr. Chriss W. Street is
a Class II director whose terms expires at the 1999 Annual Meeting. Mr. A.
Richard Pantuliano is the sole Class III director whose term expires at the 1998
Annual Meeting. Directors who are employees of the Company do not receive any
compensation for serving on the Board of Directors of the Company.
It is the intention of the persons named as proxies to vote their
proxies for the election as a Class III director Mr. A. Richard Pantuliano. Mr.
Pantuliano is currently a director, and has consented to continue to serve as a
director if elected.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE
FOR THE NOMINEE LISTED BELOW.
CLASS III: NOMINEE FOR A THREE-YEAR TERM EXPIRING AT THE YEAR 2001
ANNUAL MEETING OF STOCKHOLDERS
A. Richard Pantuliano (Age 53)
In October 1996, Mr. Pantuliano founded ARP Associates, a company
specializing in human resources consulting. Since October 1996 Mr. Pantuliano
has served as principal of ARP Associates. From 1968 to 1996, Mr. Pantuliano
held various senior management human resources positions with ITT Corporation.
Mr. Pantuliano currently renders independent consulting services to Fruehauf
Trailer Corporation, a company in which Mr. Street is the Chairman of the Board
of Directors, President and Chief Executive Officer. Mr. Pantuliano has served
as a director of the Company since May 1997 and currently serves on the
Compensation Committee of the Board of Directors.
THE FOLLOWING ARE INCUMBENT DIRECTORS WHOSE TERMS
ARE NOT EXPIRING AT THE 1998 ANNUAL MEETING
William H. Boucher (Age 66)
Mr. Boucher is a Class I director whose term expires at the 2000 Annual
Meeting. Mr. Boucher is currently a self-employed consultant providing services
to the dental, behavioral medicine and pharmaceutical industries. From February
1994 to September 1994, he served as Vice President - Sales for Foundation
Health Pharmaceutical Services, a health maintenance organization ("HMO"), and
was Vice President - Sales for Diagnostek, Inc., a mail-order pharmacy company,
from June 1991 to January 1994. Mr. Boucher was also Vice President - Sales for
Qual-Med, an HMO, from May 1990 to June 1991, and was Vice President Sales and
Marketing for PCS, Inc., a pharmacy processing company, from April 1980 to
September 1989. Mr. Boucher has served as a director of the Company since
January 1994 and currently serves on the Audit Committee and Compensation
Committee of the Board of Directors.
J. Marvin Feigenbaum (Age 48)
Mr. Feigenbaum is a Class I director whose term expires at the 2000
Annual Meeting. Mr. Feigenbaum has served as the Chairman and Chief Executive
Officer of Nu-Tech Bio Med, Inc. since June 1994. For the prior five years
thereto, Mr. Feigenbaum acted as an independent consultant in the medical and
4
<PAGE> 8
healthcare industry generally. Mr. Feigenbaum has over 25 years experience in
the healthcare industry. Mr. Feigenbaum is also the Chief Executive Officer of
Physicians Clinical Laboratories, Inc. ("PCL"), a general clinical laboratory
located in the State of California. PCL had, prior to Mr. Feigenbaum's
appointment, filed for relief under Chapter 11 of the United States Bankruptcy
Code where it operated as a debtor in possession through October 3, 1997. PCL's
securities are not publicly traded. Mr. Feigenbaum has served as a director of
the Company since March 1994 and currently serves on the Audit Committee and
Compensation Committee of the Board of Directors.
Chriss W. Street (Age 48)
Mr. Street is a Class II director whose term expires at the 1999 Annual
Meeting. Mr. Street has been employed by the Company as Chairman, President and
Chief Executive Officer of Comprehensive Care Corporation since 1994. Mr. Street
has served as a director, member of the stock option committee, and member of
the compensation committee of Nu-Tech Bio Med, Inc., a company in which Mr.
Feigenbaum is Chairman, President, and Chief Executive Officer. In June 1996,
Mr. Street joined the Board of Directors of Fruehauf Trailer Corporation. On
October 7, 1996, Fruehauf Trailer Corporation filed for relief under Chapter 11
of the United States Bankruptcy Code and subsequently, Mr. Street was named
Chairman, President, and Chief Executive Officer. Fruehauf Trailer Corporation
has been operating as a debtor in possession since October 1996, but filed a
Plan of Reorganization on July 28, 1998. The Plan of Reorganization was approved
on September 16, 1998. Mr. Street has served as a director of Drug Use is Life
Abuse since November 1997. Mr. Street is the founder and principal of Chriss
Street & Company, an investment banking corporation specializing in corporate
reorganization, factoring and securities trading. Mr. Street served as a board
member of the Orange County Employee's Retirement System between February 1996
and December 1997. Mr. Street served as a member of the Board of Directors of
StreamLogic Corporation (formerly known as Micropolis Corporation), from
February 1996 to May 1997. Mr. Street is a graduate of the University of
California, Irvine and the Stanford Business School Executive Program.
BOARD MEETINGS AND DIRECTORS' COMPENSATION
During the fiscal year ended May 31, 1998, the Board of Directors of the
Company held 11 meetings in person or by telephone. In addition, the Board of
Directors took actions by written consent on 6 occasions. Each director attended
more than 75% of the meetings of the Board of Directors and the committees on
which he served during his period of service.
During fiscal 1998, each non-employee director was compensated at the
rate of $1,000 per month of service, with committee chairmen each receiving an
additional $500 per month. Directors were required to attend at least three of
the five regular Board meetings, and were not compensated for attendance at
committee meetings or meetings conducted telephonically.
During fiscal 1999, each non-employee director will be compensated at
the rate of $1,000 per month of service. In addition, each non-employee director
will be compensated at the rate of $1,000 for each Board meeting attended and
$500 for each Board meeting conducted telephonically in which they participate.
Each non-employee director will also be compensated at the rate of $1,200 for
each committee meeting attended. Chairpersons of committees created by the Board
of Directors will be compensated at the rate of $3,000 per annum.
In April 1995, Mr. Feigenbaum was appointed Vice Chairman of the Board
of Directors for which he is paid an additional $1,500 per month.
Pursuant to the Company's Directors Stock Option Plan, directors who are
not employees receive an Initial Grant of 10,000 shares and an Annual Grant of
5,000 shares. In addition, the Vice Chairman is granted
5
<PAGE> 9
with each annual grant, options to purchase 3,333 shares of the Company's Common
Stock. Each chairman of a committee of the Board of Directors is granted with
each annual grant, options to purchase 8,333 shares of the Company's Common
Stock. Each non-employee director (other than the chairman) who serves on a
committee of the Board of Directors is granted with each annual grant, options
to purchase 2,500 shares of the Company's Common Stock.
BOARD COMMITTEES
Audit Committee. The audit committee of the Board of Directors currently
consists of Messrs. Feigenbaum and Boucher. The committee reviews the report of
the auditors' findings following the close of the audit and thereafter submits a
report of such findings to the Board of Directors. It also makes a
recommendation to the Board of Directors on the selection of independent public
accountants for the subsequent year. The audit committee met 5 times during
fiscal 1998.
Compensation Committee. The compensation committee of the Board of
Directors currently consists of Messrs. Boucher, Feigenbaum and Pantuliano. The
compensation committee recommends compensation for executives and the issuance
of stock options under existing plans and the modification of any such plans.
The compensation committee met nine times during fiscal 1998.
The entire Board serves as the nominating committee and stockholders
wishing to recommend candidates for Board membership should submit, in
accordance with the Company's Restated Bylaws, timely written notice containing
the required information including the name of the candidate and his or her
background and qualifications to the Board of Directors, c/o Secretary of the
Company, 1111 Bayside Drive, Suite 100, Corona del Mar, California 92625.
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's directors, executive officers and persons who own more than 10 percent
of the Company's Common Stock to file reports of ownership and changes in
ownership of such securities with the Securities and Exchange Commission ("SEC")
and the New York Stock Exchange, Inc. Such persons are also required by SEC
regulations to furnish the Company with copies of all Section 16(a) forms they
file. Based solely on a review of the copies of such forms furnished to the
Company or written representations that no Forms 5 were required, Management
believes that from June 1, 1997 through May 31, 1998, all of the Company's
directors, officers and 10 percent shareholders complied with all applicable
Section 16(a) filing requirements.
REPORT OF THE COMPENSATION COMMITTEE
REGARDING COMPENSATION OF
EXECUTIVE OFFICERS OF
COMPREHENSIVE CARE CORPORATION
The Company maintains a three-member compensation committee (the
"Committee") composed of non-employee directors. The Committee made
recommendations regarding all of the compensation of the Company's executives
during fiscal 1998. The Board of Directors did not materially disagree with any
such recommendations. For fiscal 1998 the Committee was composed of William H.
Boucher, J. Marvin Feigenbaum and A. Richard Pantuliano.
OVERVIEW AND PHILOSOPHY
The Committee believes that a compensation program that enables the
Company to attract and retain outstanding executives in the healthcare industry
will assist the Company in meeting its long-range objectives,
6
<PAGE> 10
thereby serving the interests of the Company's stockholders. The Committee's
compensation-related decisions in fiscal 1998 primarily involved awarding its
executives base salaries designed to compensate those executives fairly and
competitively.
The Committee approves compensation objectives and policy for all key
employees and determines compensation amounts, including cash compensation,
incentive compensation, and stock option grants, for the Company's executive
officers.
The Committee meets regularly to review both cash and non-cash
compensation for each executive, and solicits and analyzes period reports from
external consultants regarding the appropriateness of compensation levels and
decisions. The Company's primary objective is to maximize stockholder value over
time by developing a comprehensive business strategy coupled with general
compensation policies and practices that are linked to and consistent with the
Company's defined business strategy.
The Company's overall pay philosophy is to provide rewards that (1) are
linked to both the Company performance and individual performance, (2) align
employee interests with the interests of its stockholders, (3) are sufficient to
attract and retain needed high-quality employees, and (4) provide a mix of cash
and potential stock ownership tied to the long-term as well as immediate
business strategy.
EXECUTIVE OFFICER COMPENSATION
The key principles used by the Committee in structuring compensation
packages and targets of executive officers and key management are as follows:
- Long-term and at risk focus so that a significant portion of
executive pay is focused toward the long-term strategic objectives,
with the realization of rewards only as an extension of shareholder
interests.
- Management development - support of compensation opportunities
structured to attract and retain individuals who can maximize the
creation of stockholder value, and motivate employees to attain
company and individual objectives.
- Equity at risk - linking of corporate performance and individual
rewards, to instill ownership.
- Recognition of individual contributions as well as overall company
results toward identified business results.
- Competitive position of both base salary and total compensation with
the healthcare industry.
The Committee uses these principles to review and approve appropriate changes of
compensation policy and packages.
COMPONENTS OF EXECUTIVE COMPENSATION
The components of executive compensation at the Company include (1) base
salaries, (2) annual incentive bonuses, (3) long-term incentives, and (4) other
broad-based compensation plans.
BASE SALARIES
The Company's executive officers receive base salaries as compensation
for the skills, knowledge and experience that they bring to their positions.
Base salaries paid to the Company's executive officers are
7
<PAGE> 11
established by the Committee in conjunction with recommendations by the
Company's executive officers, and are not linked to Company or individual
performance objectives. Base salaries are intended to be maintained at or
slightly above the median of the range of salaries for similar positions at
public companies that are in the same lines of business as the Company and are
of similar size. Such companies include those listed in the Comparable Company
Index in the Performance Graph that appears herein.
Increases in base salary are intended to be annual and consistent with
the individual performance of the executive. From time to time, salary increases
may be made to reflect changes in an executive's skills, knowledge and
experience, increase in duties and responsibilities, and extraordinary demands
on time during the preceding fiscal year. Aggregate growth is designed to be
competitive with industry trends and reflective of the overall performance of
the Company.
ANNUAL INCENTIVE BONUSES
In the past years, the Company sought to adopt an annual incentive bonus
program that would increase total cash compensation for executives based upon
objective improvements of the Company's results of operations. In Fiscal 1998,
the Company adopted a new annual incentive bonus program for executive officers
and key members of management. At the start of each fiscal year, the Committee,
in consultation with senior management, establishes target levels of corporate
performance. This target is then translated to a threshold and maximum level of
performance with a target opportunity for each executive officer based upon
their level of responsibility, potential contribution to the success of the
Company, and competitive practices. The target opportunity consists of both
Company financial performance (net profit) and individual objectives tied to
strategic project activity. The individual's actual award is determined at the
end of the fiscal year based upon an assessment of both Company and individual
performance. Participation is restricted to Assistant Vice Presidents and above.
LONG-TERM INCENTIVES
The Company provides long-term incentives to its executives through
established programs designed to encourage executives to acquire and hold shares
of Common Stock of the Company. Long-term incentives are in the form of stock
options granted at fair market value or higher. Executive officers and key
management are provided an initial grant at the time of hire or appointment with
an annual review for additional grants to replenish vested and exercised shares.
The timing and number of options granted under the Company's stock option plan
typically takes into account the Company's performance, the executive's
contribution to such performance and the total long-term compensation previously
granted to each executive.
OTHER COMPENSATION PLANS
The Company maintains several broad-based employee benefit plans,
including the Company's 401(k) Plan, in which the executive officers are
permitted to participate on the same terms as other employees.
FISCAL 1998 CHIEF EXECUTIVE OFFICER COMPENSATION
During fiscal 1998, Chriss W. Street served as Chief Executive Officer
of the Company. Mr. Street was initially appointed Interim Chief Executive
Officer on May 6, 1994 and was appointed Chief Executive Officer on June 21,
1994. On August 25, 1994, Mr. Street was also appointed President of the
Company. In view of Mr. Street's prior and continuing commitment to his
investment banking firm and his position with Fruehauf Trailer Corporation, the
Board has allowed him to divide his time between the Company and these other
activities. This report discusses the principles applicable to Chief Executive
Officer compensation generally as well as specific considerations relating to
the compensation awarded Mr. Street.
8
<PAGE> 12
The Committee believes Mr. Street's compensation as Chief Executive
Officer appropriately reflects his outstanding performance during his tenure
with the Company in face of the condition of the company and challenges which he
inherited upon initially joining the Company. Under Mr. Street's leadership the
Company restructured its marketing focus toward managed care and continued to
reduce its administrative expenses. The Company also successfully recruited
senior management and restructured existing business units.
In determining Mr. Street's base salary, annual bonuses and equity
grants, the Committee considered the Company's overall performance and Mr.
Street's individual performance as characterized in the same measures described
above for determining executive compensation. The Committee also considered the
compensation received by chief executive officers of other healthcare companies,
as well as incentives awarded to executives for superior performance.
Mr. Street's base salary was not increased in fiscal 1998 and remained
at the level provided for in his 1995 employment agreement. Additionally, Mr.
Street did not receive an annual performance bonus award for fiscal 1998. For
the fiscal year ended May 31, 1998, Mr. Street was awarded options to purchase
120,000 shares of common stock, such options vested 100% on June 17, 1998. This
grant was coincident with the surrender for cancellation of 50,500 shares of the
Company's Common Stock which Mr. Street would otherwise have the right to
retain. On September 14, 1998, the Company entered into a new employment
agreement with Street that provides for a salary at the rate of $300,000 per
annum and an annual bonus based on the performance of the Company as follows: to
the extent that the net pre-tax earnings to the Company at the end of each
fiscal year is equal to or greater than $500,000 then Mr. Street shall receive a
bonus equal to 3% of the Company's net pre-tax earnings for such fiscal year
provided, however, that such bonus shall not exceed 50% of Mr. Street's salary
in any fiscal year. Pursuant to the terms of the agreement, Mr. Street was
granted options to purchase up to an aggregate of 100,000 shares of common stock
at an exercise price equal to $6 per share which price is approximately 150% of
the closing price of the common stock as reported on the New York Stock Exchange
on September 14, 1998. In the event that the Company's net pre-tax earnings are
equal to or greater than $1 million, 37,500 of such options vest on May 31,
1999. In addition, 37,500 of such options vest in three equal annual
installments based upon increases of at least 12.5% in the Company's market
capitalization in each fiscal year during the term of the agreement. The
remaining 25,000 options vest on the first anniversary of the grant date.
LIMITATIONS ON THE DEDUCTIBILITY OF COMPENSATION
Pursuant to the 1993 Omnibus Budget Reconciliation Act, a portion of
annual compensation payable after 1993 to any of the Company's five highest paid
executive officers would not be deductible by the Company for federal income tax
purposes to the extent such officer's overall compensation exceeds $1.0 million
per executive officer. Qualifying performance-based incentive compensation,
however, would be both deductible and excluded for purposes of calculating the
$1.0 million base. The Board of Directors has determined that no portion of
anticipated compensation payable to any executive officer in 1998 would be
non-deductible. The Board of Directors will continue to address this issue when
formulating compensation arrangements for executive officers, but believes that
the deductibility of officer compensation in excess of the $1.0 million
threshold is not likely to be an issue for the Company to address in the
foreseeable future.
CONCLUSION
The Compensation Committee believes the executive compensation policies
and programs serve the interests of the shareholders of the Company. The
Committee also believes the cash and non-cash awards have been linked to and are
commensurate with Company performance and individual efforts in achieving the
business strategy of the Company.
9
<PAGE> 13
SUBMITTED BY THE COMPENSATION COMMITTEE
OF THE BOARD OF DIRECTORS OF COMPREHENSIVE CARE CORPORATION
- ------------------------ ------------------------ -------------------------
William H. Boucher J. Marvin Feigenbaum A. Richard Pantuliano
- ------------------------ ------------------------ -------------------------
COMPENSATION COMMITTEE
INTERLOCKS AND INSIDER PARTICIPATION
During fiscal 1998, recommendations and administrative decisions
regarding the compensation of the Company's executives were made by the
Compensation Committee of the Board of Directors, which is currently comprised
entirely of persons who are not officers or employees of the Company. Mr. W.
James Nicol, who served as a director of the Company and a member of the
Compensation Committee during fiscal year 1998, served as President of the
Company from October 1989 until August 1990 and as an Executive Vice President
of the Company and in other senior management positions from 1973 through June
1989. Mr. Nicol resigned as a director on September 30, 1997.
Mr. Street is a Class II director of the Company and also its Chairman,
Chief Executive Officer and President and serves on the stock option committee
of the board of directors of Nu-Tech Bio-Med, Inc. Mr. Feigenbaum, the Company's
Vice-Chairman and also the Chairman of the Compensation Committee, is also the
Chairman of Nu-Tech Bio-Med, Inc.
PERFORMANCE GRAPH
The following is a line graph comparing the Company's total stockholder
returns to those of The New York Stock Exchange Composite Index, a Comparable
Company Index (including the Company, PMR Corporation, Magellan Health Services,
and Horizon Health Corp.) for each year in the period from June 1, 1993 and
ended May 31, 1998. Total return values were calculated based on cumulative
total return, assuming the value of the investment in the Company's Common Stock
and in each index was $100 and that all dividends were reinvested.
[GRAPH]
ASSUMES $100 INVESTED ON JUNE 1, 1993
ASSUMES DIVIDENDS REINVESTED
FIVE FISCAL YEARS ENDED MAY 31, 1998
<TABLE>
<CAPTION>
May 1993 May 1994 May 1995 May 1996 May 1997 May 1998
-------- -------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Comprehensive Care 100 81.82 103.64 134.55 203.64 147.27
Corporation
Comparable Co. 100 147.09 101.11 149.44 174.27 168.28
Index
NYSE Composite 100 105.8 121.62 155.06 193.82 252.17
</TABLE>
EXECUTIVE COMPENSATION
This section of the Proxy Statement discloses the compensation earned by
the Company's Chief Executive Officer and other executive officers of the
Company whose total salary and bonus for fiscal 1998 exceeded $100,000
(together, these persons are sometimes referred to as the "named executives").
10
<PAGE> 14
TABLE I - SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
ANNUAL COMPENSATION LONG-TERM COMPENSATION
---------------------------------------------------- ---------------------------
OTHER RESTRICTED SECURITIES LONG-TERM ALL
FISCAL SALARY BONUS ANNUAL STOCK UNDERLYING INCENTIVE OTHER
NAME AND POSITION YEAR ($) ($) COMPENSATION($) AWARDS($) OPTIONS/SARS(#) PAYOUTS($) COMPENSATION
----------------- ------ ------- ------ --------------- ----------- --------------- ---------- ------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Chriss W. Street 1998 264,263 0 6,000(1) 0 120,000 0 76,998(3)
Chairman of the 1997 245,192 15,947 5,837(1) 589,919(2) 25,000 229,508(4)
Board of 1996 207,324 0 9,225(1) 43,780 100,000 1,495(15)
Directors, (17)(18)
Chief Executive
Officer(17) and
President(17)(18)
Mary Jane Johnson 1998 110,040 20,000 0 0 37,000 0 1,012(15)
Executive Vice 1997 97,125(5) 5,000 0 0 3,000 0 331(15)
President (17)
Chief Executive
Officer (18)
H.G. Whittington, 1998 148,955(6) 20,000 0 0 19.000 0 0
M.D. 1997 50,468(7) 0 0 0 1,000 0 0
Executive Vice
President
National Medical
Director (17)
Joni S. Cummings 1998 100,025 0 18,412(8) 0 17,000 0 0
Executive Vice 1997 76,949 0 24,308(8) 0 3,000 0 0
President, 1996 18,735 0 6,154(8) 0 0 0 0
Business
Development (17)
Richard L. Powers 1998 124,661(9) 30,149 0 413,627 0 0 1,125(15)
Executive Vice 1997 128,185 87,000 49,805(10) 5,812 30,000 0 860(15)
President, Sales 1996 95,622 0 133,001(10) 15,449 0 0 0
and Marketing (18)
Stuart J. Ghertner 1998 58,455(11) 13,333 17,500(14) 0 0 0 0
Chief Operating 1997 158,958(12)(13) 21,667 27,500(14) 0 125,000 0 0
Officer (17)
Robert J. Landis 1998 0(16) 0 0 0 0 0 0
Executive Vice
President-Chief
Financial Officer
and Treasurer (17)(18)
</TABLE>
11
<PAGE> 15
- --------------------------------
(1) Represents a car allowance paid by the Company and in accordance with Mr.
Street's employment agreement.
(2) In September 1995, the Board of Directors granted and issued to its
President and Chief Executive Officer 100,000 Restricted Shares of its
Common Stock, $0.01 par value. The Restricted Shares were subject to
vesting at the rate of 5,000 Restricted Shares per fiscal year over a
20-year period. The vesting of the restricted shares was subject to
acceleration upon the occurrence of certain events of acceleration. As of
December 1997, 49,500 Restricted Shares were vested and 50,500 were
unvested, with the holder having sole voting power. In December 1997, the
Company, with the consent of Chriss W. Street, terminated a grant of the
remaining unvested shares originally granted in September 1995. Coincident
with this transaction, the Company implemented a new program to grant Mr.
Street 120,000 options of common stock at a price of $6.6875. These
options are fully vested, non-incentive stock options, exercisable on and
after June 17, 1998 and through December 8, 2007, regardless of whether
Mr. Street's employment with the Company continues through that date.
(3) Represents $75,873 of a one-time bonus for taxes payable due to the
acceleration of Restricted Shares and $1,125 in amounts contributed to Mr.
Street's 401(k) Plan Account.
(4) Represents $227,589 of a one-time bonus for taxes payable due to the
acceleration of Restricted Shares and $1,919 in amounts contributed to Mr.
Street's 401(k) Plan Account.
(5) Between August 1, 1996, and January 25, 1997, Ms. Johnson served as an
independent consultant to the Company for which she received an aggregate
compensation of $53,000.
(6) Dr. Whittington ceased to be an executive officer of the Company on August
15, 1998.
(7) Dr. Whittington was employed on January 13, 1997. Accordingly, amounts
shown for Dr. Whittington only reflect compensation that he earned from
his date of hire through the end of fiscal 1997.
(8) Represents commissions paid to Ms. Cummings.
(9) Mr. Powers ceased to be an executive officer of the Company on February
28, 1998.
(10) Represents commissions paid to Mr. Powers.
(11) Dr. Ghertner ceased to be an executive officer of the Company on September
12, 1997.
(12) Dr. Ghertner was employed by the Company on January 1, 1997. Accordingly,
amounts shown for Dr. Ghertner only reflect compensation that he earned
from his date of hire through the end of fiscal 1997.
(13) Between August 6, 1996 through December 31, 1996, Dr. Ghertner served as
an independent consultant to the Company for which he received an
aggregate compensation of $93,000.
(14) Represents compensation expense related to the vesting of options which
were not performance related.
(15) Represents amounts contributed by the Company to the indicated person's
401(k) Plan Account.
(16) Mr. Landis was employed by the Company on July 2, 1998. His compensation
includes a base salary of $150,000 per annum plus a bonus that is
performance related. The Company has granted options to
12
<PAGE> 16
purchase 87,500 shares of common stock, which become 100% vested on
January 2, 1999 and expire on July 2, 2008.
(17) Comprehensive Care Corporation.
(18) Comprehensive Behavioral Care, Inc., principal subsidiary of the Company.
TABLE II - OPTIONS HELD AT MAY 31, 1998
The following tables present information regarding the number of
unexercised options held by the Company's named executives at May 31, 1998. Two
of the Company's named executives exercised options for 59,800 shares of the
Company's Common Stock in fiscal 1998. No stock appreciation rights were granted
or held by such persons during fiscal 1998.
OPTION GRANTS IN THE LAST FISCAL YEAR
<TABLE>
<CAPTION>
% of Total Exercise
Options Granted Price Grant Date
Options to Employees in per Expiration Present
Name Granted Fiscal Year Share Date Value(1)
--------------------- ------- --------------- -------- ---------- ----------
<S> <C> <C> <C> <C> <C>
Chriss W. Street 120,000 24% $6.688 12/08/07 $2.68
Mary Jane Johnson 37,000 7% $10.875 09/06/07 $5.06
H.G. Whittington, M.D. 19,000 4% $8.000 01/23/08 $3.72
Joni S. Cummings 17,000 3% $8.000 01/23/08 $3.72
</TABLE>
- ----------------------
(1) Black-Scholes option pricing method has been used to calculate present
value as of date of grant. The present value as of the date of grant,
calculated using the Black-Scholes method is based on assumptions about
future interest rates, stock price volatility and dividend yield. There is
no assurance that these assumptions will prove to be true in the future.
The actual value, if any, that may be realized by each individual will
depend upon the market price of the Common Stock on the date of exercise.
13
<PAGE> 17
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND AGGREGATED FISCAL YEAR-END OPTION VALUE
<TABLE>
<CAPTION>
Value of
Number of Unexercisable
Unexercised In-the-Money
Shares Options at Options at
Acquired on Value Fiscal Year-End(1) Fiscal Year-End(2)
Name Exercise(#) Realized($) Exercisable/Unexercisable Exercisable/Unexercisable
------------------- ----------- ----------- ------------------------- -------------------------
<S> <C> <C> <C> <C>
Chriss W. Street(3) 39,500 534,719 125,000/120,000 257,375/412,500
Mary Jane Johnson - - 3,000/37,000 0
H. G. Whittington, M.D. - - 1,000/19,000 0/40,375
Joni S. Cummings - - 3,000/17,000 0/36,125
Richard L. Powers 20,300 54,594 0 0
</TABLE>
- -------------------------
(1) The numbers of options granted prior to October 21, 1994, have been
adjusted for the ten-for-one reverse stock split which was effective
October 21, 1994.
(2) Calculated on the basis of the closing sale price per share for the
Company's Common Stock on the New York Stock Exchange of $10.125 on May 31,
1998. Value was calculated on the basis of the difference between the
option exercise price and $10.125 multiplied by the number of shares of
Common Stock underlying the respective options.
(3) Exercisable options include options for 40,000, 25,000, 20,000, 20,000 and
20,000 shares granted in the Company's 1988 Incentive Stock Option and
Non-statutory Plans at $6.25, $7.875, $8.00, $10.00 and $12.00 per share,
respectively. Unexercisable options represent the 120,000 options granted
during fiscal 1998.
CONTRACTS WITH EXECUTIVES
On September 14, 1998 the Company entered into a new employment
agreement with Mr. Chriss W. Street, the President and Chief Executive Officer
of the Company. The agreement has a term expiring on November 30, 2001. Mr.
Street's employment agreement provides for a salary at the rate of $300,000 per
annum and an annual bonus based on the performance of the Company as follows: to
the extent that the net pre-tax earnings to the Company at the end of each
fiscal year is equal to or greater than $500,000 then Mr. Street shall receive a
bonus equal to 3% of the net pre-tax earnings of the Company for such fiscal
year provided, however, that such bonus shall not exceed 50% of Mr. Street's
base salary in any fiscal year. Pursuant to the terms of the agreement, Mr.
Street was granted options to purchase up to an aggregate of 100,000 shares of
common stock at an exercise price equal to $6 per share which price is
approximately 150% of the closing price of the common stock as reported on the
New York Stock Exchange on September 14, 1998. In the event that the Company's
net pre-tax earnings are equal to or greater than $1 million, 37,500 of such
options vest on May 31, 1999. In addition, 37,500 of such options vest in three
equal annual installments based upon increases of at least 12.5% in the
Company's market capitalization in each fiscal year during the term of the
agreement. The remaining 25,000 options vest on the first anniversary of the
grant date. In addition, Mr. Street is provided with health insurance and other
benefits and a policy of life insurance. He also receives an auto allowance of
$600 per month and reimbursement for expenses incurred on behalf of the Company
and in connection with the performance of his duties. The agreement obligates
the Company to use its best efforts to cause Mr. Street to continue to be
elected as a Class II director, and as Chairman of its Board of Directors. The
agreement provides that the Company procure Directors and Officers Liability
Insurance in an amount not less than $1.0 million.
14
<PAGE> 18
Mr. Street's employment agreement provides that in the event of a change of
control of the Company as defined therein, Mr. Street will be paid a severance
benefit equal to the greater of (i) the balance of his base salary for the
remainder of the unexpired term of his agreement or (ii) two times the sum of
Mr. Street's then prevailing base salary.
On September 14, 1998, the Company entered into an employment agreement
with Robert J. Landis, the Executive Vice President and Chief Financial Officer
and Treasurer of the Company and Chief Financial Officer of the Company's
principal subsidiary, Comprehensive Behavioral Care, Inc. The agreement has a
term expiring on January 2, 2000. Mr. Landis' employment agreement provides for
a salary at the rate of $150,000 per annum and a bonus of up to an amount not
exceeding $50,000. Pursuant to the terms of the agreement, Mr. Landis was
granted options to purchase 87,500 shares of common stock at an exercisable
price equal to $10 per share. Such options fully vest on January 2, 1999 and
expire on July 2, 2008. In addition, subject to Mr. Landis being employed by the
Company, Mr. Landis shall be granted options annually to purchase 25,000 shares
of common stock at an exercisable price equal to the closing price of the common
stock on the New York Stock Exchange on the date of grant. Such option shall
vest at the rate of 50% on the first anniversary date of the grant and 50% on
the second anniversary date of the grant. In addition, Mr. Landis is provided
with health insurance and other benefits and a policy of life insurance. Mr.
Landis' employment agreement provides that in the event of a change in control
of the Company as defined therein or his termination without cause, Mr. Landis
will be paid a severance benefit equal to the greater of (i) the balance of his
base salary for the remainder of the unexpired term of his agreement or (ii)
twelve (12) months base salary, together with his bonus.
INDEMNIFICATION AGREEMENT
In connection with the Company's indemnification program for executive
officers and directors, Messrs. Street, Landis, Carnaham, Boucher, Feigenbaum,
and Pantuliano, and Ms. Johnson, Cummings, Dolan, Cheney and Watson, as well as
four former directors and five former executive officers, are entitled to
indemnification and are beneficiaries of the officers and directors
indemnification trust. The Company considers it desirable to provide each
Indemnitee with specified assurances that the Company can and will honor the
Company's obligations under the indemnification agreements, including a policy
of insurance to provide for directors and officers liability coverage.
STOCK OPTION PLANS
The 1995 Incentive Plan, as amended December 8, 1997 (the "1995 Plan")
provides for the granting of options to eligible employees and consultants to
the Company. Options granted as incentive stock rights, stock options, stock
appreciation rights, limited stock appreciation rights and restricted stock
grants under the 1995 Plan may qualify as an ISO under Section 422A of the
Internal Revenue Code. Options for ISOs may be granted for terms up to ten years
and are generally exercisable in cumulative increments of 33 percent each year.
Options for NSOs may be granted for terms up to 13 years. Options for ISOs must
equal or exceed the fair market value of the shares on the date of grant, and 65
percent in the case of other options. The 1995 Plan also provides for the full
vesting of all outstanding options under certain change of control events. The
maximum number of shares authorized for issuance under the 1995 Plan is 600,000.
In September 1995, the Board of Directors granted and issued to its
President and Chief Executive Officer, 100,000 Restricted Shares of its Common
Stock, $0.01 par value. Such grant of Restricted Shares was issued from the
Company's 1995 Incentive Plan and was ratified by the stockholders at the 1995
Annual Meeting. The Restricted Shares were subject to vesting at the rate of
5,000 shares per fiscal year (the "Annual Vested Shares") over a 20-year period.
The vesting of the Restricted Shares was subject to acceleration upon the
occurrence of certain events of acceleration. As of December 1997, 49,500
Restricted Shares were vested and 50,500 were unvested, with the holder having
sole voting power. During such month, the Company, with the consent of Mr.
Street, terminated a grant of the remaining unvested shares originally granted
in September
15
<PAGE> 19
1995. Coincident with this transaction, the Company implemented a new program to
grant Mr. Street 120,000 options of common stock at a price of $6.6875. These
options are fully vested, non-incentive stock options, exercisable on and after
June 17, 1998 and through December 20, 2002, regardless of whether Mr. Street's
employment with the Company continues through that date.
The Company has a non-qualified stock option plan for its outside
directors (the "Directors' Stock Option Plan" or the "Directors' Plan"). The
Directors' Plan provides for the Company to grant to each non-employee director
options as follows: (1) each individual serving as a non-employee director as of
the effective date were granted a non-qualified stock option to purchase 10,000
shares of Common Stock ("Initial Grant"); (2) each individual who first becomes
a non-employee director on or after the effective date, will be granted, at the
time of such election or appointment a non-qualified stock option to purchase
10,000 shares of Common Stock ("Initial Grant"); (3) commencing with the 1995
annual meeting of the Company's stockholders, each individual who at each annual
meeting of the Company's stockholders remains a non-employee director will
receive an additional non-qualified stock option to purchase 2,500 shares of
Common Stock. Commencing with the 1996 annual meeting, the number of options
awarded annually to all non-employee directors was increased from 2,500 shares
to 5,000 shares and provided for an annual grant of special service options to
the Vice Chairman of the Board of 3,333 shares and to each committee chairman of
8,333 shares and each committee member of 2,500 shares. In addition, each
non-employee director will automatically be granted an option to purchase 10,000
shares upon joining the Board of Directors and options to purchase 5,000 shares
on the date of the annual meeting. Each non-qualified stock option is
exercisable at a price equal to the Common Stock's fair market value as of the
date of grant. Initial grants vest annually in 25 percent increments beginning
on the first anniversary of the date of grant, provided the individual is still
a director on those dates. Annual grants will become 100 percent vested as of
the first annual meeting of the Company's stockholders following the date of
grant, provided the individual is still a director as of that date. An optionee
who ceases to be a director shall forfeit that portion of the option
attributable to such vesting dates on or after the date he or she ceases to be a
director. The maximum number of shares authorized for issuance under the
Directors' Plan is 200,000.
EXECUTIVE TERMINATION AGREEMENTS
For information related to the termination benefits for Mr. Street and
Mr. Landis, see the description of the employment agreements between the Company
and Mr. Street and Mr. Landis under "Contracts with Executives."
CERTAIN TRANSACTIONS
In September 1995, the Board of Directors granted and issued to Chriss
W. Street, its President and Chief Executive Officer, 100,000 Restricted Shares
of its Common Stock, $0.01 par value. The Restricted Shares were subject to
vesting at the rate of 5,000 Restricted Shares per fiscal year over a 20-year
period. The vesting of the restricted shares were subject to acceleration upon
the occurrence of certain events. As of December 1997, 49,500 Restricted Shares
were vested and 50,500 were unvested, with the holder having sole voting power.
In December 1997, the Company, with the consent of Chriss W. Street, terminated
the grant of the remaining unvested shares originally granted in September 1995.
Coincident with this transaction, the Company implemented a new program to grant
Mr. Street 120,000 options of common stock at a price of $6.6875. These options
are fully vested, non-incentive stock options, exercisable on and after June 17,
1998 and through December 8, 2007, regardless of whether Mr. Street's employment
with the Company continues through that date.
For a description of the employment agreements approved by the Board of
Directors on September 14, 1998 between the Company and Mr. Street and the
Company and Mr. Landis, please see "Contracts with Executives".
16
<PAGE> 20
PROPOSAL 2 - PROPOSAL TO AMEND THE COMPREHENSIVE CARE CORPORATION
1995 INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES
OF COMMON STOCK ISSUABLE THEREUNDER
TO 1,000,000 SHARES
The Board of Directors unanimously approved, subject to stockholder
approval, an amendment to the Comprehensive Care Corporation 1995 Incentive Plan
as amended on December 8, 1997 (the "Plan") to increase the number of shares
issuable thereunder from 600,000 to 1,000,000 shares. The Plan, as amended, is
described under "Stock Option Plans", and the Resolution to be approved by the
stockholders of the Company amending the Plan is annexed as Appendix A to this
Proxy Statement.
The Amendment to the Plan is necessary by reason of the fact that of the
600,000 shares authorized under the Plan, options to acquire an aggregate of
520,575 shares of Common Stock have been issued, leaving 79,425 shares remaining
which could be issued under the Plan. The remaining number of shares authorized
under the Plan are viewed by management to be insufficient to provide for
additional awards to attract and retain key executive personnel and to
incentivize management personnel to maximize the value of the Company for all of
it stockholders. See "Executive Compensation - Summary Compensation Table" and
"Option Grants in the Last Fiscal Year" for information relating to stock option
grants to the Company's named executive officers. Management is of the belief
that, in view of the anticipated expansion of the Company's operations over the
next several years, the recent relocation of certain financial and
administrative functions to Tampa, Florida and the associated need to recruit
new middle management personnel, the challenge and mission of existing executive
officers will increase. The Plan is designed to augment the Company's existing
compensation programs and is intended to enable the Company to have its
executives, key employees and consultants participate in the growth and success
of the Company through awards under the Plan.
It is further felt that the grant of options under the Plan will improve
the Company's ability to reward management and to attract new additions to
management as well as to replace management, and is particularly appropriate
given the Company's plan for the continued expansion of the Company's business.
Rather than adopting a new plan entirely, management has deemed it
advisable to increase the number of shares available under the 1995 Incentive
Plan.
The affirmative vote of the holders of a majority of the shares of the
Company's Common Stock issued and outstanding on the record date, voting
together as a single class, is required for the approval of this proposal.
THE BOARD OF DIRECTORS DEEMS THIS PROPOSAL NUMBER 2 TO BE IN THE BEST
INTEREST OF THE COMPANY AND ITS STOCKHOLDERS AND RECOMMENDS A VOTE "FOR"
APPROVAL THEREOF.
INDEPENDENT AUDITORS
Ernst & Young LLP ("Ernst & Young") initially became engaged as the
Company's independent auditors for fiscal year 1995. Ernst & Young has performed
the audit of the consolidated financial statements of the Company and its
subsidiaries for the fiscal years ended May 31, 1995, 1996, 1997 and 1998, and
has been selected to perform the audit for the year ended May 31, 1999.
ANNUAL REPORT
The 1998 Annual Report to Stockholders, including consolidated financial
statements for the fiscal year ended May 31, 1998 and the Company's annual
report on Form 10-K (without exhibits thereto), has been mailed with this Proxy
Statement. The Company will provide copies of exhibits to the Annual Report on
Form
17
<PAGE> 21
10-K, but will charge a reasonable fee per page to any requesting stockholder.
Stockholders may make such request in writing to the Secretary of the Company,
4200 West Cypress Street, Suite 300, Tampa, Florida 33607.
OTHER MATTERS
The Board of Directors knows of no other matters to be brought before
the 1998 Annual Meeting. However, if any other business properly comes before
the Annual Meeting, the persons named in the accompanying form of proxy will
vote or refrain from voting thereon in accordance with their judgment pursuant
to the discretionary authority given them in the proxy.
STOCKHOLDER PROPOSALS FOR 1999 ANNUAL MEETING
Stockholder proposals to be submitted for inclusion in the 1999 proxy
materials and consideration at the 1999 Annual Meeting of Stockholders must be
received by the Company not later than July 20, 1999. Such proposals should be
directed to the Secretary of the Company, 4200 West Cypress Street, Suite 300,
Tampa, Florida 33607.
By Order of the Board of Directors,
/s/ Courtney Watson
Courtney Watson
Secretary
September 30, 1998
Tampa, Florida
<PAGE> 22
APPENDIX A
RESOLUTION TO AMEND THE
COMPREHENSIVE CARE CORPORATION
1995 INCENTIVE PLAN
RESOLVED, that in accordance with the provisions of Paragraph 20 of the
Comprehensive Care Corporation (the "Company") 1995 Incentive Plan (the "Plan"),
originally adopted at the Annual Meeting of Stockholders held on November 9,
1995 and as amended on December 8, 1997, Paragraph 3 relating to the number of
shares of Common Stock issuable under the Plan is herewith amended to increase
the number of such shares from 600,000 to 1,000,000 shares of Common Stock, and
such Paragraph 3, as amended, shall read as follows:
"3. Stock subject to the Plan
The shares that may be issued upon exercise of options and
rights which may be sold under the Plan shall not exceed in the
aggregate of 1,000,000 shares of Common Stock, as adjusted to
give effect to the anti-dilution provisions contained in Section
12 hereof. Such shares may be authorized and unissued shares, or
shares purchased by the Company and reserved for issuance under
the Plan. If a stock option or incentive stock right for any
reason expires or is terminated without having been exercised in
full, or if the shares issued pursuant to restricted stock
purchase agreements are repurchased by the Company in accordance
with the terms thereof, those shares relating to an unexercised
stock option or incentive stock rights or shares which have been
repurchased, shall again become available for grant and/or sale
under the Plan."
<PAGE> 23
COMPREHENSIVE CARE CORPORATION
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
FOR THE 1998 ANNUAL MEETING OF STOCKHOLDERS ON NOVEMBER 17, 1998
The undersigned hereby appoints Chriss W. Street and Courtney Watson, or
either of them, proxies, with power of substitution, to vote the shares of
common stock of Comprehensive Care Corporation which the undersigned is entitled
to vote at the 1998 Annual Meeting of Stockholders on November 17, 1998, and any
adjournment thereof, as follows:
1. PROPOSAL 1: Election of Director:
[ ] FOR the election as a director the following:
Class III: Nominee for a 3-year term expiring in the year 2001:
A. Richard Pantuliano
[ ] WITHHOLD AUTHORITY to elect the nominee listed above.
PROPOSAL 2. Proposal to amend the 1995 Incentive Plan to increase the number
of shares available from 600,000 shares to
1,000,000 shares.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
3. With discretionary power in the transaction of such other business as may
properly come before the annual meeting.
(Continued and to be signed on reverse side)
<PAGE> 24
THIS PROXY, PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED HEREON. IF NO
DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR PROPOSALS 1 AND 2. THE PROXIES
MAY VOTE IN THEIR DISCRETION AS TO OTHER MATTERS WHICH MAY PROPERLY COME BEFORE
THE 1998 ANNUAL MEETING.
Dated: , 1998
-------------------------------
Signature
-------------------------------
Signature (if held jointly)
-------------------------------
Title or authority (if
applicable)
NOTE: Please sign exactly as
name appears hereon. If shares
are registered in more than one
name, the signature of all
persons are required. A
corporation should sign in its
full corporate name by a duly
authorized officer, stating his
or her title. Trustees,
guardians, executors and
administrators should sign in
their official capacity, giving
their full title as such. If a
partnership, please sign in the
partnership name by an
authorized person.
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY PROMPTLY, USING THE ENCLOSED
ENVELOPE.
NO POSTAGE REQUIRED IF MAILED IN THE UNITED STATES.
